Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer

Viale, G.G.VialeGiobbie-Hurder, A.A.Giobbie-HurderGusterson, B. A.B. A.GustersonMaiorano, E.E.MaioranoMastropasqua, M. G.M. G.MastropasquaSonzogni, A.A.SonzogniMallon, E.E.MallonColleoni, M.M.ColleoniCastiglione, MonicaMonicaCastiglioneRegan, M. M.M. M.ReganPrice, K. N.K. N.PriceBrown, R. W.R. W.BrownGolouh, R.R.GolouhCrivellari, D.D.CrivellariKarlsson, P.P.KarlssonÖhlschlegel, C.C.ÖhlschlegelGelber, R. D.R. D.GelberGoldhirsch, A.A.GoldhirschCoates, A. S.A. S.Coates2024-10-252024-10-252009https://boris-portal.unibe.ch/handle/20.500.12422/161464en600 - Technology::610 - Medicine & healthAdverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancerarticle10.7892/boris.11580910.1093/annonc/mdp317